Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Sigyn Therapeutics submits international patent application for ChemoPrep and ChemoPure

Sigyn Therapeutics (OTCQB:SIGY) submitted a Patent Cooperation Treaty (PCT) application for the technologies it is developing to enhance the clinical benefit of chemotherapeutic drugs. Chemotherapy is the most commonly...

October 5, 2023

Developments

Anixa’s breast cancer vaccine featured in Yahoo Life news

Anixa Biosciences’ (NASDAQ:ANIX) breast cancer vaccine was featured in an Oct. 3 article in Yahoo Life news. The article introduces Ohioan Jennifer Davis as the first person in the world to receive a breast cancer...

October 4, 2023

Developments

Hepion in $5-million registered direct offering

Hepion Pharmaceuticals (NASDAQ:HEPA) entered into a securities purchase agreement with a healthcare-focused institutional investor for the purchase of 980,393 shares of the company at a purchase price of $5.10 per share...

September 29, 2023

Developments

PharmaJet partner, Scancell, posts positive data from Phase 2 advanced melanoma trial

PharmaJet partner, Scancell, reported positive data from the first phase of a Phase 2 clinical trial evaluating PharmaJet’s needle-free vaccine delivery system for treatment of advanced melanoma. The Phase 2 study’s...

September 28, 2023

Developments

Profound Medical gets FDA 510(k) clearance for first TULSA-PRO AI module, Thermal Boost

Profound Medical (NASDAQ:PROF; TSX:PRN) received FDA 510(k) clearance for its Thermal Boost module for use in conjunction with TULSA-PRO. Thermal Boost enables predictable, customized ablation at the prostate capsule...

September 25, 2023

Developments

IntelGenx receives first RIZAFILM purchase order from U.S. partner Gensco

IntelGenx (TSX:IGX; OTCQB:IGXT) reported that it received the first purchase order (PO) for RIZAFILM from its U.S. commercial partner, Gensco Pharma. The company expects to ship the order to Gensco in the first quarter...

September 21, 2023

Developments

Hepion’s rencofilstat demonstrates anti-cancer activity

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that rencofilstat demonstrated anti-cancer activity across 86% of cancer types in a high-throughput screen on 850 cancer cell lines. At the Broad Institute of MIT and...

September 21, 2023

Developments

IntelGenx receives FDA GDUFA date for partnered buprenorphine buccal film

IntelGenx’s (TSX:IGX; OTCQB:IGXT) buprenorphine buccal film – for which an amendment to the abbreviated to new drug application (ANDA) requesting priority review has been filed by Chemo Research through its agent and...

September 20, 2023

Developments

Hepion discovers novel rencofilstat action in liver cancer

Hepion Pharmaceuticals (NASDAQ:HEPA) reported new research findings that discovered a mechanism by which the company’s lead drug candidate, rencofilstat, may exert anti-cancer activity. The research examined...

September 20, 2023

Developments

Anixa forms cancer business advisory board

Anixa Biosciences (NASDAQ:ANIX) formed a cancer business advisory board (CBAB) with a roster of renowned cancer advocates, executives and physicians to guide the company’s clinical and business development...

September 19, 2023

Developments

Mati completes manufacturing facility; prepares for Phase 3 nepafenac trial

Closely-held Mati Therapeutics completed a dedicated manufacturing facility for products formulated using the company’s Evolute sustained ocular drug delivery platform. Mati expects that the 10,000-square-foot facility...

September 15, 2023

Developments

Hepion’s rencofilstat shows positive outcomes in idiopathic pulmonary fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive findings from a translational research study assessing the effects of rencofilstat on lung tissue obtained from patients with idiopathic pulmonary fibrosis (IPF)...

September 14, 2023

Developments

OKYO completes enrollment in Phase 2 dry eye clinical trial

OKYO Pharma (NASDAQ:OKYO) completed full enrollment of patients in the randomized portion of the Phase 2 clinical trial of topical ocular, OK-101, to treat dry eye disease (DED). A total of 240 patients were enrolled in...

September 8, 2023

Developments

Rani posts successful drug delivery of high-capacity pill

Rani Therapeutics Holdings (NASDAQ:RANI) reported three new positive preclinical studies that support development of a high-capacity oral biologics device, known as the RaniPill HC, a version of the RaniPill capsule...

September 8, 2023

Developments

Opus Genetics doses first patient with gene therapy in LCAS

Closely-held Opus Genetics dosed the first patient in its Phase 1/2, first-in-human clinical trial of OPGx-LCA5, an adeno-associated virus 8 vector designed to precisely deliver a functional LCA5 gene to the outer...

September 7, 2023

Developments

Arcutis posts positive long-term roflumilast cream results in AD

Arcutis Biotherapeutics (NASDAQ:ARQT) reported positive interim results from the INTEGUMENT-OLE long-term, open-label study of roflumilast cream 0.15% in adults and children ages six years and older with atopic...

September 7, 2023

Developments

Cantor boosts biotech research with Josh Schimmer, Eric Schmidt

Cantor Fitzgerald bolstered its healthcare and biotech equity research team with the addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D. “Having two of the most highly regarded analysts in the biotechnology...

September 6, 2023

Developments

Palisade Bio in GI-licensing deal with Giliant Pharma

Palisade Bio (NASDAQ:PALI) entered into a licensing agreement with closely-held Giliant Pharma for the exclusive worldwide rights to develop, manufacture and commercialize Giiant’s proprietary targeted prodrug platform...

September 6, 2023

Developments

Tonix fails Phase 2 pain study; holds out hope in fatigue

Tonix Pharmaceuticals Holding’s (NASDAQ:TNXP) TNX-102 SL did not achieve the pre-specified primary endpoint of improving Long COVID pain intensity scores at week 14 in the Phase 2 PREVAIL study. However, TNX-102 showed...

September 5, 2023

Developments

Plus Therapeutics initiates Part B of ReSPECT-LM Phase 1/2a trial for LM

Plus Therapeutics (NASDAQ:PSTV) treated the first patient in Part B (Cohort 4) of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of rhenium obisbemeda for the treatment of leptomeningeal metastases (LM) from...

September 5, 2023

Developments

Sage in reorganization to support launch of ZURZUVAE, advance pipeline

Sage Therapeutics (NASDAQ:SAGE) plans to reorganize its business operations and pipeline priorities to support goals for long-term business growth, including the planned commercial launch of ZURZUVAE for women with...

August 31, 2023

Developments

Ampio Pharmaceuticals unveils reverse stock split

The board of Ampio Pharmaceuticals (NYSEA:AMPE) approved a 20-to-1 reverse stock split of the company’s common stock, to be effective at close on Sept. 11. Ampio’s common stock is expected to begin trading on a...

August 31, 2023

Subscribe